Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease

Shinzaki, Shinichiro; Fujii, Toshimitsu; Bamba, Shigeki; Ogawa, Maiko; Oshita, Masahide; Tanaka, Hiroki; Ozeki, Keiji; Takahashi, Sakuma; Kitamoto, Hiroki; Kani, Kazuhito; Nanjo, Sohachi; Sugaya, Takeshi; Sakakibara, Yuko; Inokuchi, Toshihiro; Kakimoto, Kazuki; Yamada, Akihiro; Yasuhara, Hisae; Yokoyama, Yoko; Yoshino, Takayuki; Matsui, Akira; Nakamura, Misaki; Tomizawa, Takashi; Sakemi, Ryosuke; Kamata, Noriko; Hibi, Toshifumi

doi:10.5217/ir.2018.00044

Cited by 12 publications

(8 citation statements)

References 33 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A multicenter retrospective cohort study showed that H. pylori eradication did not worsen IBD activity. [ 11 ] However, there have been no reports involving pediatric patients with IBD. We report a pediatric patient with worsened UC activity following the eradication of H. pylori.…”

Section: Discussionmentioning

confidence: 99%

Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Helicobacter pylori (H. pylori) prevalence is lower in patients with inflammatory bowel disease (IBD) than in those without IBD, suggesting that H. pylori plays a protective role in IBD. It has been reported that IBD may occur due to H. pylori eradication; however, it is unclear whether H. pylori eradication increases the incidence of IBD. Moreover, the effect of H. pylori eradication on IBD activity is unclear. Case presentation An 11-year-old boy diagnosed with ulcerative colitis (UC) was in clinical remission, with treatment involving 5-aminosalicylic acid. Fecal calprotectin (FC) level had decreased to 33.2 mg/kg, indicating mucosal healing. At age 12, he experienced epigastric pain on an empty stomach, which was relieved with dietary intake. His FC level was elevated without UC symptoms, such as diarrhea and bloody stools. He was diagnosed with H. pylori duodenal ulcer. H. pylori eradication (clarithromycin and amoxicillin for 7 days and a proton-pump inhibitor) led to symptom improvement the day after treatment initiation. However, he developed diarrhea and his FC level remained high despite improvement in duodenal ulcer symptoms and endoscopic findings of H. pylori eradication. Colonoscopy results indicated UC relapse. Conclusions H. pylori eradication may worsen UC activity. However, further studies are required as this case report involved only one pediatric patient with increased UC activity after H. pylori eradication.

show abstract

Section: Discussionmentioning

confidence: 99%

Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, the severity of IBD, UC in particular, increased after H. pylori eradication [54]. The same information was provided by Shinzaki S et al, who found an improvement of IBD condition only in subjects who did not undergo eradication therapy [55]. The IBD phenotype-modifying capabilities of H. pylori were shown in studies demonstrating that fibro-stenotic and fistulizing CD as well as risk of bowel resections and number of relapses were significantly lower in H. pylori-infected subjects [48].…”

Section: Inflammatory Bowel Diseasesmentioning

confidence: 57%

Extra-Gastric Manifestations of Helicobacter pylori Infection

Gravina

Priadko

Ciamarra

et al. 2020

JCM

View full text Add to dashboard Cite

Helicobacter Pylori (H. pylori) is a Gram-negative flagellated microorganism that has been extensively studied since its first isolation due to its widespread diffusion and association with numerous diseases. While the bacterium is proved to be a causative factor for a number of gastric diseases such as gastritis, gastric adenocarcinoma, and MALT-lymphoma, its role at other gastrointestinal levels and in other systems is being thoroughly studied. In this article, we reviewed the latest published clinical and laboratory studies that investigated associations of H. pylori with hematologic diseases such as Vitamin B12- and iron-deficiency anemia, primary immune thrombocytopenia, and with a number of dermatologic and ophthalmic diseases. In addition, the putative role of the bacterium in inflammatory bowel diseases, esophageal disorders, metabolic, diseases, neurologic diseases and allergy were outlined.

show abstract

“…In addition, the authors mentioned that careful observation after eradication therapy is necessary, especially for patients with active IBD who underwent eradication therapy”. 34 Systemic combined amoxicillin and metronidazole reduced the local inflammatory load and OPG levels in patients with localized periodontitis. 35 Thus, this study investigated the effect of sequential H. pylori eradication therapy on serum OPG levels in patients with H. pylori infection and co-existing inflammatory bowel disease.…”

Section: Discussionmentioning

confidence: 98%

Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with Helicobacter pylori infection and co-existing inflammatory bowel disease

et al. 2021

View full text Add to dashboard Cite

Objective To investigate the effect of sequential Helicobacter pylori eradication therapy on serum osteoprotegerin levels in patients with H. pylori infection and co-existing inflammatory bowel disease (IBD). Methods Three groups of patients were involved in this observational cross-sectional study: IBD (n = 83), H. pylori infection (HP, n = 68), and H. pylori infection with co-existing IBD (HP + IBD, n = 52). These groups were compared with a normal control group (NC, n = 50). Serum osteoprotegerin, serum bone alkaline phosphatase (BALP), and fecal calprotectin (FC) levels were measured. Results Serum osteoprotegerin levels were significantly correlated with the simple endoscopic score for Crohn’s disease and Mayo score for ulcerative colitis. The receiver operating characteristic analysis of osteoprotegerin revealed high values for the area under the curve, sensitivity, and specificity. Discriminant analysis illustrated that osteoprotegerin levels significantly differentiated patients with IBD from healthy controls. Osteoprotegerin and FC levels distinguished the IBD and HP + IBD groups from the NC and HP groups. Conclusions Sequential eradication therapy did not affect serum osteoprotegerin levels in patients with H. pylori infection and co-existing IBD. Serum osteoprotegerin elevation might be a marker for IBD development in patients with past or current H. pylori infection.

show abstract

Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease

Cited by 12 publications

References 33 publications

Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer

Ulcerative colitis relapse after Helicobacter pylori eradication in a 12-year-old boy with duodenal ulcer

Extra-Gastric Manifestations of Helicobacter pylori Infection

Effect of sequential eradication therapy on serum osteoprotegerin levels in patients with Helicobacter pylori infection and co-existing inflammatory bowel disease

Contact Info

Product

Resources

About